26.7 C
Vientiane
Thursday, August 28, 2025
spot_img
Home Blog Page 354

Official Established of AI for Human International Foundation

Building the world’s first “Technology + Governance” dual-wheel drive platform to promote implementable governance standards

HONG KONG, July 21, 2025 /PRNewswire/ — The AI for Human International Foundation (the “Foundation”) was officially established on July 9, 2025 with the goal of building the world’s first “Technology + Governance” dual-wheel drive platform in order to unite the strengths of all sectors to solve the ethical, regulatory and governance issues brought about by the rapid development of artificial intelligence, and to build a new paradigm for the governance and development of artificial intelligence.

The AI for Human International Foundation was officially established on July 9, 2025, by Mr. Nicholas Chan Hiu-fung, Hong Kong Deputy to the National People's Congress (from left), Ms. Sun Mingjun, President of the Zhongguancun Intelligent Artificial Intelligence Research Institute and Mr. Fung Yui Kong, Founder of Pangaea Connectivity Technology Limited.
The AI for Human International Foundation was officially established on July 9, 2025, by Mr. Nicholas Chan Hiu-fung, Hong Kong Deputy to the National People’s Congress (from left), Ms. Sun Mingjun, President of the Zhongguancun Intelligent Artificial Intelligence Research Institute and Mr. Fung Yui Kong, Founder of Pangaea Connectivity Technology Limited.

The Foundation is co-founded by Mr. Nicholas Chan Hiu-fung, Hong Kong Deputy to the National People’s Congress, Ms. Sun Mingjun, President of the Zhongguancun Intelligent Artificial Intelligence Research Institute, and Mr. Fung Yui Kong, Founder of Pangaea Connectivity Technology Limited (Stock Code: 1473). The Foundation is a non-profit organization established for the purpose of integrating resources, introducing talents, and sharing technologies through marketization. Facing the global demand for AI technologies, the Foundation built the world’s first “technology + governance” dual-wheel drive platform, solving the ethical, regulatory, and governance issues brought about by the rapid development of AI, and formulating corresponding laws and policies to promote the advancement of AI technologies, so as to establish an open, safe, cooperative and shared international platform to promote the healthy development of global AI technologies.

Functions and missions of the Foundation:

  1. To conduct in-depth research on the governance aspects of Artificial Intelligence in terms of data security, privacy protection and generative AI regulation, to propose effective governance and development solutions, and to actively publish reports to enhance the influence of the industry.
  2. To organize Salon meetings around AI intellectual property to strengthen the exchange of AI intellectual property and increase the awareness of protection.
  3. To launch industry surveys and research, form a working group composed of senior experts, draft industry standards and technical specifications, widely solicit opinions, and continuously improve standards and regulatory frameworks.
  4. To construct an international exchange platform, organize scene matching, resource matching, etc., and host international conferences to promote the globalization of technology, information sharing and experience exchange, and to strengthen the cohesion of the industry.
  5. To establish a talent exchange and training program to attract and cultivate highly skilled personnel to provide human resources assurance for the development of artificial intelligence.

Ms. Sun Mingjun, Chairman of the Foundation and President of the Zhongguancun Intelligent Artificial Intelligence Research Institute said, “The purpose of the Foundation is to address the global demand for AI technology, and then to bridge the gap between supply and demand for AI, such as governance, ethics, and global legal compliance, as well as technology, and how it can be deeply connected in different contexts. Based on the background of this industry, we initiated the establishment of the Foundation to realize the work of global artificial intelligence technology promotion.”

Mr. Nicholas Chan Hiu-fung, Honorary Founding Chairman of the Foundation and Hong Kong Deputy to the National People’s Congress, said, “In this era of artificial intelligence, we are all trying to explore the way forward. We are now in the era of Industry 4.0. In the supply chain and daily life, we are also exploring how to work more efficiently and economically. Artificial intelligence is very close and relevant to our lives. It requires the collaboration of many parties, including a sound policy environment, good laws and regulations, as well as talents, resources, technology, creativity and capital, etc. Hong Kong is endowed with these unique conditions. Hong Kong is a place where talents converge. When students and scientific research talents are learning and applying, it is very important to have a channel for the transformation of scientific research into application scenarios.”

Regarding the development potential of AI in the application landscape, Mr. Fung Yui Kong, Vice Chairman of the Foundation and Founder of Pangaea Connectivity Technology Limited, pointed out, “Artificial intelligence has developed particularly rapidly in the past two to three years due to the large-scale construction of data centers both in China and in the United States. Computing speed is the key in the development process. Power is of course the most important thing, and data speed also needs to be improved because computing is fast and furious. We believe that there are not many scenarios that apply to AI at the day-to-day level. We believe that there will be a wider range of applications in the next few years, and this application level will require a lot of computing power in the information center. We set up the Foundation at this time because we see that there is enormous room for development in the future”.

Regarding the Foundation’s future focus, President Sun said, “In the second half of this year, the Foundation will plan to release case reports on artificial intelligence + environmental protection governance and practices, as well as reports on artificial intelligence + healthcare governance and practices, etc. Through artificial intelligence, some practical cases such as environmental protection, sewage treatment and air treatment, etc., can be fundamentally resolved.  We hope to first use Hong Kong as a base, facing the world such as countries of the BRICS and the Belt and Road Initiative, etc., to fully promote the practice to the world, and initially set up a liaison mechanism to establish the artificial intelligence industry standards and evaluation platform, so that the whole society can build confidence in artificial intelligence to help this technology put into practice.”

VEOCEL™’s Lyocell Fibers for Enhanced Cleaning Take Center Stage at World of Wipes 2025

  • VEOCEL™ Lyocell fibers for Enhanced Cleaning to debut at WOW 2025 in Columbus, Ohio
  • Innovation provides a new solution for high-performance, environmentally responsible cleaning products

LENZING, Austria, July 21, 2025 /PRNewswire/ — At the upcoming World of Wipes® (WOW) 2025 in Columbus, Ohio, Lenzing’s flagship specialty nonwovens brand, VEOCEL™, will introduce VEOCEL™ Lyocell fibers for Enhanced Cleaning, a new innovation designed to support the next generation of high-performance surface cleaning and disinfecting wipes.

Aligned with VEOCEL™’ s innovation theme, “Unleash Possibilities”, this breakthrough is designed to inspire Lenzing’s partners to rethink product design through the use of advanced cellulosic fibers. Derived from wood-based[1] raw materials, they offer an alternative to fossil-based synthetics and contribute to the reduction of avoidable plastic[2] waste in wipe applications.

Delivering Enhanced Cleaning Performance[3]

VEOCEL™ Lyocell fibers for Enhanced Cleaning are engineered to improve wiping performance through stronger and denser fabrics and enhance the end-user experience. These fibers ensure even liquid distribution, helping to reduce excess dripping and provide greater control during cleaning. Compared to fossil-based alternatives, each wipe can clean up to twice the surface area, offering significantly improved disinfecting efficacy.

A key factor contributing to the performance of these new VEOCEL™ fibers is their compatibility with active or functional ingredients commonly used in disinfectants such as quaternary ammonium compounds (quats). While many other cellulosic fibers require additional chemical treatments to achieve similar functionality, VEOCEL™ fibers for Enhanced Cleaning are designed through careful selection of raw materials and optimized production methods to exhibit minimal and consistent binding to active ingredients. This seemingly simple yet impactful advancement in fiber properties allows VEOCEL™’s cellulosic fibers to be used in applications previously dominated by plastic-based materials. 

In addition, these fibers provide excellent wet strength and form stability[4], maintaining structural integrity even at lower basis weights. Altogether, these characteristics make them exceptionally well-suited for demanding cleaning environments—from household and personal care to institutional and industrial settings.

All VEOCEL™ Lyocell fibers are wood-based[5] and biodegradable[6], produced in a closed-loop, resource-efficient process with low emissions to air and water[7]. The Enhanced Cleaning variant maintains these high environmental standards while delivering superb technical performance.

“With the introduction of our VEOCEL™ Lyocell fibers for Enhanced Cleaning, we are unleashing new possibilities for our customers to choose cellulosic fibers in disinfecting wipes, empowering excellent performance while advancing their commitment to environmental responsibility,” said Patricia A. Sargeant, Executive Vice President Nonwovens at Lenzing AG.

Discover More at WOW 2025

Lenzing will showcase VEOCEL™ Lyocell fibers for Enhanced Cleaning at WOW 2025, July 21–24, at Tabletop #405. Attendees can learn how this innovation supports hygiene, efficiency, and responsible material use.

Axel Russler, Innovation Project Manager Nonwovens, presented the fiber’s development, performance testing and real-world applications in an INDA-hosted pre-show webinar titled “Advanced Cellulosic Solution for Disinfection Wipes”. 

 

About the Lenzing Group

 

The Lenzing Group stands for the responsible production of specialty and premium fibers based on regenerated cellulose. As an innovation leader, Lenzing is a partner of global textile and nonwoven manufacturers and drives many new technological developments. The Lenzing Group’s high-quality fibers are the raw material for a wide range of textile applications – ranging from functional, comfortable, and fashionable clothing through to durable and sustainable home textiles. TÜV-certified biodegradable and compostable Lenzing fibers are also ideal for demanding use in everyday hygiene applications.

 

The Lenzing Group’s business model extends far beyond that of a traditional fiber producer. Together with its customers and partners, Lenzing develops innovative products along the value chain, adding value for consumers. The Lenzing Group strives for efficient utilization and processing of all raw materials and offers solutions for the transition of the textile industry from the current linear economic system to a circular economy. In order to align its commitment to limiting man-made climate change with the goals of the Paris Agreement, Lenzing has a clear, science-based climate action plan that provides for a significant reduction in greenhouse gas emissions (Scopes 1, 2, and 3) by 2030 and a net-zero target by 2050.

 

Key Facts & Figures Lenzing Group 2024

Revenue: EUR 2.66 bn

Nominal capacity (fibers): 1,110,000 tonnes

Employees (full-time equivalents): 7,816

 

TENCEL™, LENZING™ ECOVERO™, VEOCEL™, LENZING™ and REFIBRA™ are trademarks of Lenzing AG.

 

[1] Please refer to Lenzing Wood & Pulp Policy (lenzing.com).

[2] “plastic” means a material consisting of a polymer as defined in point 5 of Article 3 of Regulation (EC) No 1907/2006, to which additives or other substances may have been added, and which can function as a main structural component of final products, with the exception of natural polymers that have not been chemically modified.

[3] Compared to LENZING™ Lyocell Standard fibers

[4] Compared to LENZING™ Lyocell Standard fibers

[5] Please refer to Lenzing Wood & Pulp Policy (lenzing.com).

[6] A range of LENZING™ Lyocell and Viscose fibers for nonwoven applications are certified by TÜV AUSTRIA to be biodegradable in soil, freshwater and marine conditions and compostable under home and industrial conditions.

[7] These results were calculated using the Higg Materials Sustainability Index (Higg MSI) tools provided by the Sustainable Apparel Coalition. The Higg MSI tools assess impacts of materials from cradle-to-gate for a finished material (e.g. to the point at which the materials are ready to be assembled into a product). However, this figure only shows impacts from cradle to fiber production gate. VEOCEL™ branded fibers’ LCA results are represented by TENCEL™/ECOVERO™ data based on Higg MSI database v3.7 (December, 2023).

 

Gorilla Technology Concludes Legal Action Against Culper Research via Settlement Agreement


London, United Kingdom – Newsfile Corp. – July 21, 2025 – Gorilla Technology Group Inc. (NASDAQ: GRRR) (“Gorilla” or the “Company”), today announced that it has resolved its previously disclosed litigation against Culper Research (“Culper”) and its founder, Christian Lamarco.

The Company issued the following statement:

Subsequent to a report published on April 4, 2025 by Culper Research, Gorilla Technology filed a lawsuit against Culper and its founder, Christian Lamarco, on April 16, 2025. Given recent developments, including, but not limited to, the release of Gorilla’s 20F filing dated April 30, 2025 and Gorilla’s earnings release dated June 18, 2025, Gorilla Technology Group and Culper Research have agreed to resolve their litigation via a confidential non-monetary settlement.

Jay Chandan, Chairman & CEO, added:

“We are pleased to put this matter behind us. Gorilla has spent this year doing what matters most, executing our strategy and delivering results. With over $5.6 billion in active pipeline, new capital secured and a growing global customer base, we are not just moving forward, we are accelerating.

The company remains committed to maintaining high standards of transparency and performance as it enters its next phase of growth. This resolution clears the runway, and I intend to use it.”

Gorilla recently hosted a webinar to share updates on its recent momentum, including a $5.6 billion global pipeline of active opportunities and continued U.S. expansion with wide-scale public sector relationships. Moreover, Gorilla’s strong first quarter earnings released on June 18, 2025 reinforce its continued momentum and operational progress. For more information on Gorilla’s business updates, please visit the Company’s investor relations website here.

About Gorilla Technology Group Inc.

Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.

Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.

For more information, please visit our website: Gorilla-Technology.com.

Public Relations Contact:
Samantha Dowd
Prosek Partners
GRRR@prosek.com

Investor Relations Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
GRRR@redchip.com

The issuer is solely responsible for the content of this announcement.

About Gorilla Technology Group Inc.

Monarq Asset Management Appoints Sam Gaer as CIO to Lead Directional Strategy

NEW YORK, July 21, 2025 /PRNewswire/ — Monarq Asset Management (“Monarq”), a leading multi-strategy investment firm formerly known as MNNC Group, is pleased to announce the appointment of Sam Gaer as Chief Investment Officer to lead its Directional Investment Strategy. With over 25 years of leadership experience across institutional trading, market infrastructure, and systematic asset management, Sam Gaer brings deep expertise to support Monarq’s next phase of growth.

Following a decade of success in delta-neutral and market-making strategies, Monarq is expanding its directional capabilities to capture a broader range of risk-adjusted returns. The strategy emphasizes high-conviction themes, asymmetric exposures, and tactical volatility overlays—positioning the firm to navigate evolving market conditions with precision.

Monarq’s Directional Strategy has delivered strong performance year-to-date, adhering to disciplined risk and capital allocation. Backed by global institutional capital across its USD and BTC-denominated funds, Monarq is now scaling access to Directional as a complementary source of absolute returns within its platform.

“We’re excited to welcome Sam to the team,” said Shiliang Tang, CEO and Managing Partner. “His leadership enhances our ability to compound asymmetric returns and anticipate key catalysts in the digital asset space.”

Mr. Gaer previously co-managed BlockTower Capital’s flagship fund and founded Katana Financial, a leading systematic trading firm. He also served as CIO at FINRA and EVP/CIO at NYMEX, where he led major technological transformations and strategic initiatives. He holds a degree in Corporate Finance from the Wharton School of the University of Pennsylvania.

About Monarq Asset Management
Monarq Asset Management, formerly MNNC Group, is a multi-strategy digital asset investment manager focused on generating consistent, risk-adjusted returns through all market conditions. Managed by former executives from firms such as LedgerPrime, Tower Research, and BlockTower Capital, the team offers extensive experience in quantitative trading, volatility strategies, and digital market structure.

Media Contact: info@monarq-am.com

FS Investments announces rebrand to “Future Standard,” signaling vision for the next era in private markets

  • Rebrand highlights firm’s evolution, transformational combination with Portfolio Advisors and commitment to delivering differentiated performance
  • New Private Market Outlook urges investors to embrace a more specialized approach to private markets

PHILADELPHIA, July 21, 2025 /PRNewswire/ — FS Investments, an $86 billion global alternative asset manager, today announced its rebrand and renaming to Future Standard. The move marks a major milestone in the firm’s evolution into one of the alternative investment industry’s leading platforms for private equity, credit and real estate investments and solutions.

Future Standard will operate under a unified identity following its transformational combination with Portfolio Advisors, delivering an integrated experience across the firm’s investment strategies. Both firms have long been known as first-movers in the private markets, and the rebrand signals a commitment by the combined firm to remain at the leading edge for clients.

“Future Standard reflects what has always been at our core—a relentless drive to serve clients by uncovering differentiated opportunities that drive performance,” said Michael Forman, Chief Executive Officer. “Our expertise and access enable us to deliver the attractive returns our clients seek by uncovering opportunities others overlook.”

With deep specialization in the U.S. middle market, Future Standard is focused on a segment that is essential to economic growth but remains underrepresented in many investor portfolios. The middle market includes more than 200,000 companies generating between $10 million and $1 billion in annual revenue. As 99% of these companies are privately held, it makes access difficult without the right relationships, expertise and structure.

“In today’s crowded market, standing out demands clarity, conviction and a commitment to challenging convention,” said Stephen Tisdalle, Chief Marketing Officer. “Future Standard reflects how we help optimize our clients’ portfolios with unique and untapped opportunities. This brand gives us the voice and platform to bring our specialization, skill and ambition to our clients and to the entrepreneurs powering the U.S. economy.”

The firm’s new brand leverages its legacy of innovation and industry firsts, including launching the first private business development company (BDC) and the largest non- traded credit REIT. Future Standard’s investment approach combines deep domain expertise with thoughtful product design, providing clients with access to opportunities across liquidity profiles and market cycles.

“While much is changing, the core of who we are and where we operate remains the same,” Forman added. “With specialized teams across asset classes and a strong distribution infrastructure, we are focused on investor outcomes and leading the way in private markets access and performance.”

Private Markets Outlook

Future Standard today also released its latest Private Markets Outlook, “Follow the  Value, Not the Herd,” which examines how policy uncertainty and macroeconomic risks are impacting dealmaking. Beneath this cyclical uncertainty, the report identifies a more significant shift: a new investment imperative is emerging in private markets. Many allocators are flocking to large, brand-name managers—but as the report underscores, capturing real value in this next market phase will require a different approach.

“Nearly half of all private capital raised globally this year has flowed into megafunds, intensifying the challenge of generating attractive returns,” said Mike Kelly, Chief Investment Officer. “We believe the next cycle of alpha will be led by operators who understand how to drive real value—through pricing power, margin expansion, and executional excellence. At a time when policy and geopolitical uncertainty persist, we believe the most compelling opportunities for investors lie in the U.S. middle market, where operational rigor, sector specialization, and manager skill drive differentiated returns.”

In this environment, operational expertise and domain specialization will be the key to outperformance. Future Standard’s analysis shows that in private equity, large-cap managers have underperformed their smaller peers in both median and top-end returns. In both private credit and real estate, smaller funds show greater upside. Meanwhile, higher interest rates are reshaping the investment terrain, compressing equity returns and shifting value toward lenders.

As the global investment landscape evolves, the imperative is clear: managers must think differently and embrace the complexity of what comes next.

Contact information:
Marc Hazelton or Melanie Hemmert 
media@futurestandard.com

ABOUT FUTURE STANDARD

Future Standard is a global alternative asset manager serving institutional and private wealth clients, investing across private equity, credit and real estate. With a 30+ year track record of value creation and over $86 billion in assets under management, we back the business owners and financial sponsors that drive growth and innovation across the middle market, transforming untapped potential into durable value.1

Visit futurestandard.com to learn more.                                  

1 Total AUM estimated as of March 31, 2025.        

Cenra Healthcare and Dr. Reddy’s Strengthen Strategic Partnership to Expand Access to Medicines in Taiwan

TAIPEI, July 21, 2025 /PRNewswire/ — Cenra Healthcare, the sales and marketing arm of Cenra Inc. (TWSE: 3716), today announced the deepening of its long-standing collaboration with the global pharmaceutical company Dr. Reddy’s Laboratories (Taiwan) Ltd (Dr. Reddy’s). Since the partnership began in 2020, the two companies have worked closely to introduce a diverse range of high-quality generic drugs and innovative formulations to patients in Taiwan, with a shared commitment to broadening access to affordable and clinically valuable treatments.

Left – Cenra Healthcare General Manager Lucas Lin; Right – Dr. Reddy’s Group Country Head Satheeshkumar Sriharan.
Left – Cenra Healthcare General Manager Lucas Lin; Right – Dr. Reddy’s Group Country Head Satheeshkumar Sriharan.

“We are proud to strengthen our collaboration with Dr. Reddy’s, one of the world’s leading pharmaceutical companies with strong R&D capabilities,” said Lucas Lin, General Manager of Cenra Healthcare. “With Cenra Healthcare’s broad market coverage and strong presence in Taiwan’s healthcare landscape, we are well positioned to support our partners in promoting access to essential medicines. This partnership is built not just on product alignment, but on a shared belief in patient-centric care — delivering affordable, high-quality treatment options backed by long-term trust and mutual values.”

Over the past five years, Cenra Healthcare and Dr Reddy’s have successfully introduced a number of key therapies in the field of oncology, including chemotherapy agents, hormone therapies, and targeted treatments for prostate cancer, breast cancer, ovarian cancer, and hematological malignancies. The collaboration aligns with the National Health Insurance Administration’s (NHIA) policy to encourage the use of generic drugs in cancer treatment, thereby enhancing medicine supply resilience and safeguarding patient access.

Looking ahead, Cenra Healthcare and Dr. Reddy’s will continue to deepen their partnership by introducing additional  proven therapies across multiple therapeutic areas. Cenra Healthcare is also actively partnering with other leading global pharmaceutical companies to bring more affordable and much-needed medicines to patients in Taiwan – advancing its vision of empowering health equity and delivering hope and trust to patients and families.

About Cenra Healthcare
Cenra Healthcare, established in 2004 as the sales and marketing arm of Cenra Inc., is a leader in providing comprehensive healthcare solutions tailored to meet the diverse needs of individuals in Taiwan and beyond. Cenra Healthcare specializes in the distribution of high-quality pharmaceuticals and innovative healthcare products, ensuring accessibility and affordability for all.

Founded in 1952, Cenra Inc. (TWSE: 3716; formerly China Chemical & Pharmaceutical Co., Ltd.) is one of the leading healthcare companies in Taiwan, with its subsidiaries and affiliates covering a wide range of areas, including human and veterinary pharmaceuticals, active pharmaceutical ingredients, health supplements, over-the-counter (OTC) drug products, household and beauty products, and elderly care services. Cenra is driven by a vision of “Empowering health equity, propelling a healthier world for all,” and is committed to delivering impactful health solutions and enhancing public health through partnerships and strategic alliances. For more information, please visit cenra.com.

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) was founded in 1984 and is headquartered in Hyderabad, India. Guided by its mission ‘Good Health Can’t Wait’, it is committed to providing affordable and innovative medicines. Its portfolio of products and services includes active pharmaceutical ingredients (APIs), generics (including biosimilars and OTC products), innovative products, and custom pharmaceutical services. Its key therapeutic focus areas are gastrointestinal, cardiovascular, and oncology. Dr. Reddy’s has a global presence spanning over 80 countries, with major markets including the United States, India, Russia & other CIS countries, China, Brazil, and Europe.

Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem


HONG KONG SAR – Media OutReach Newswire – 21 July 2025 – Chengdu Kanghua Biological Products Co., Ltd. (Stock Code: 300841.SZ) announced that Shanghai Healthcare M&A Fund (“the M&A Fund”) intends to acquire the Company through a strategic agreement. Leveraging its substantial resource and financial strength, the M&A Fund plans to support Kanghua Biological’s established product portfolio, accelerate sales of its mature products, and develop industry synergies between Shanghai and Chengdu. The goal is to rapidly expand a diversified vaccine pipeline and build an integrated vaccine ecosystem that combines proven commercialized products with best-in-class R&D capabilities.

Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological

Dual-Driven Strategy: “Commercialization + Innovation” to Build a Leading Vaccine Ecosystem
The vaccine industry is an essential pillar of public health with high entry barriers, stringent oversight, and extended development cycles – all factors contributing to its significant growth potential. As a leading domestic vaccine producer, Kanghua Biological’s flagship product – human diploid cell rabies vaccine – stands as China’s first domestically developed premium vaccine with over a decade of safe application, established market presence and nationwide distribution. The Company also maintains a robust global innovation pipeline, having successfully licensed its recombinant hexavalent norovirus vaccine overseas. This strategic acquisition, focused on critical segments of the vaccine value chain, will strengthen its strategic positioning. The M&A Fund is committed to supporting Kanghua Biological in leveraging its core product line while harnessing the combined strengthens of Shanghai and Chengdu to accelerate the formation of a next-generation vaccine industry ecosystem.

Twin-City Collaboration: Combining “R&D + Manufacturing” to Create a New Industrial Framework
This acquisition marks a significant step to drive Shanghai and Chengdu biopharmaceutical cooperation. Post-transaction, Kanghua Biological will capitalize on Shanghai’s advanced R&D resources and access to top-tier scientific talent and global capital to enhances its industrial capabilities, manufacturing capacity, and market penetration. The M&A Fund will consolidate diverse industrial assets to promote Kanghua Biological’s integration with Shanghai’s R&D and clinical networks, creating an end-to-end collaborative system that spans from “clinical R&D to commercialization” and accelerates the development of a full industrial value chain.

Dual-Channel Empowerment: Driving Corporate Value through “M&A + Integration”
“This transaction goes beyond a typical corporate acquisition, it represents a transformative catalyst for industrial upgrading,” commented Li Chen, Co-President of the M&A Fund. “This exemplifies the complementary strengths created by resource-empowered consolidation. With deep biopharmaceutical, financial, R&D, and global network expertise, Shanghai Healthcare M&A Fund will create significant synergies with Kanghua Biological’s technologies, products, manufacturing, and domestic distribution to have an outsized impact on the sector.”
Hashtag: #SIICCapital #ChengduKanghuaBiological #ShanghaiHealthcareM&AFund

The issuer is solely responsible for the content of this announcement.

About Shanghai Healthcare M&A Fund

A core component of Shanghai’s state-owned capital fund network, Shanghai Healthcare M&A Fund is managed by SIIC Capital, a subsidiary of SIIC Group. The M&A Fund targets Shanghai’s biopharmaceutical sector, aligning government policy objectives with industrial needs by fostering collaboration with leading industry companies, strengthening sector clusters, and enabling asset restructuring. Through capital infusion, improving governance, optimizing management, and executing M&A, the M&A Fund backs “anchor” companies to build complementary and reinforcing links in the value chain, driving the ongoing transformation of specialized subsectors.

About Chengdu Kanghua Biological Products Co., Ltd.

Chengdu Kanghua Biological Products Co., Ltd. is a biopharmaceutical company engaged in research, manufacture and commercialization of biological products. Established in 2004, the company operates an in-house testing center and GMP-certified bacterial and viral vaccine production facilities. Its marketed portfolio includes the ACYW135 meningococcal polysaccharide vaccine and a freeze-dried human diploid cell rabies vaccine. Kanghua holds GMP certification from China’s National Medical Products Administration, has participated in numerous scientific research projects and has been granted patents for over 100 technologies.

Multiplier Wins Gold and Silver Stevie® Awards for Redefining Global Hiring

The company was awarded Gold for HR Technology Solution Provider of the Year and Silver for Global HR Solution Provider of the Year.

NEW YORK, July 21, 2025 /PRNewswire/ — Multiplier, a leading global employment platform, today announced it has been honored with both a Gold Stevie® Award for HR Technology Solution Provider of the Year and a Silver Stevie® Award for Global HR Solution Provider of the Year in the prestigious 10th annual Stevie® Awards for Great Employers. These accolades recognize Multiplier’s pivotal role in transforming how companies access, manage, and scale global talent.

The Stevie® Awards are the world’s premier business awards, celebrating excellence in the workplace across a wide range of industries and functions. This recognition reflects Multiplier’s impact in democratizing global hiring, making it accessible, cost-effective, and compliant for companies worldwide.

“We’ve always believed that talent knows no borders,” said Sagar Khatri, Co-founder and CEO of Multiplier. “The Stevie Awards are a powerful validation of the technology we’ve built at Multiplier to turn that belief into reality. We’re removing the friction from global hiring, and giving companies the tools to scale across markets with speed and confidence.”

Since its inception in 2020, Multiplier has been on a mission to simplify the complexities of international hiring. The company’s platform helps businesses to onboard, manage, and pay employees and contractors across more than 150 countries and in over 120 currencies. Through a single, automated, and compliance-first solution, Multiplier significantly reduces the total cost of ownership by up to 35% and provides unparalleled support with dedicated Customer Success Managers and 24/7 human-led assistance.

The Gold Stevie® Award for HR Technology Solution Provider of the Year specifically highlights Multiplier’s cutting-edge platform, lauded for its intuitive, AI-led user experience that streamlines global hiring and payroll processes. The Silver Stevie® Award for Global HR Solution Provider of the Year acknowledges the company’s broader impact in enabling frictionless international expansion for businesses of all sizes, fundamentally changing the landscape of global employment.

“Multiplier doesn’t just tick the innovation boxes; it was born from real-world frustration and built with human empathy at its core,” said one of the Stevie Award Judges. “The awards and recognitions (IEC, Everest, G2, Fast Company) are impressive, but the real strength lies in how they’ve quietly redefined what global employment feels like: fast, compliant, and deeply people-first.”

Details about the Stevie Awards for Great Employers and the list of 2025 Stevie winners

are available at www.StevieAwards.com/HR.

END

About Multiplier

Multiplier is a global employment platform for HR leaders and professionals who need an easy, fast, and cost-effective way to onboard, hire, manage and pay the best global talent across 150+ countries. Through its best-in-class EOR, COR, Global Payroll, and compliance technology, plus person-to-person support and hyper-local employee benefits, Multiplier empowers its customers to hire the best global talent and build a world of limitless opportunity.

About the Stevie Awards

Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Technology Excellence and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.